{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:38:19Z","timestamp":1761766699725,"version":"3.37.3"},"reference-count":4,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T00:00:00Z","timestamp":1586822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"DOI":"10.1093\/jac\/dkaa120","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T12:42:32Z","timestamp":1583757752000},"page":"3698-3699","source":"Crossref","is-referenced-by-count":3,"title":["Comment on: Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study"],"prefix":"10.1093","volume":"75","author":[{"given":"Filippo","family":"Del Puente","sequence":"first","affiliation":[{"name":"Department of Health Science (DISSAL), Infectious Disease Clinic, University of Genoa, Genoa, Italy"},{"name":"Department of Infectious Diseases, Galliera Hospital, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7086-710X","authenticated-orcid":false,"given":"Marco","family":"Berruti","sequence":"additional","affiliation":[{"name":"Department of Health Science (DISSAL), Infectious Disease Clinic, University of Genoa, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[{"name":"Department of Infectious Tropical Diseases and Microbiology, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1436-5089","authenticated-orcid":false,"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[{"name":"Department of Health Science (DISSAL), Infectious Disease Clinic, University of Genoa, Genoa, Italy"},{"name":"Infectious Diseases Clinic, Policlinico Hospital San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,4,14]]},"reference":[{"key":"2020111305061071100_dkaa120-B1","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1093\/jac\/dkz224","article-title":"Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study","volume":"74","author":"Katlama","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020111305061071100_dkaa120-B2","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"2020111305061071100_dkaa120-B3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1080\/23744235.2019.1569257","article-title":"Is it time to re-think the use of etravirine in patients with available genotypic resistance test?","volume":"51","author":"Del Puente","year":"2019","journal-title":"Infect Dis (Lond)"},{"key":"2020111305061071100_dkaa120-B4","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1093\/jac\/dkr248","article-title":"Ageing with HIV: medication use and risk for potential drug\u2013drug interactions","volume":"66","author":"Marzolini","year":"2011","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/12\/3698\/34291268\/dkaa120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/12\/3698\/34291268\/dkaa120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T10:06:20Z","timestamp":1605261980000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/12\/3698\/5819692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,14]]},"references-count":4,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,4,14]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa120","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,4,14]]}}}